Loading…
Reported covered position: Military Legislative Assistant and Foreign Policy Advisor to Sen. Kay Bailey Hutchison (TX); Military Legislative Assistant to Rep. Jeff Miller (FL-01).
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Right to Try Clarification Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2024 · second_quarter · Q2
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Source: Senate LDA
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Medicaid VBPs for Patients Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Medicaid VBPs for Patients Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2024 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · fourth_quarter · Q4
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · third_quarter · Q3
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE